Tarsus Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Tarsus Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||
| current assets: | ||||||||||||||||||||
| cash and cash equivalents | 96,648,000 | 175,787,000 | 94,819,000 | 176,210,000 | 181,095,000 | 193,705,000 | 224,947,000 | 226,672,000 | 106,773,000 | 65,997,000 | 71,660,000 | 169,489,000 | 245,363,000 | 175,010,000 | 171,332,000 | 183,801,000 | 176,735,000 | 156,179,000 | 168,129,000 | 86,329,000 |
| marketable securities | 284,495,000 | 232,129,000 | 196,557,000 | 140,742,000 | 142,485,000 | 104,819,000 | 2,495,000 | 20,213,000 | 71,455,000 | 135,222,000 | 145,366,000 | 57,083,000 | 291,000 | 483,000 | ||||||
| accounts receivable | 58,334,000 | 62,426,000 | 46,760,000 | 29,159,000 | 29,529,000 | 29,885,000 | 16,621,000 | 5,362,000 | 2,500,000 | 17,000 | 17,000 | 17,000 | 20,000,000 | 25,000,000 | ||||||
| inventory | 3,873,000 | 2,705,000 | 2,620,000 | 2,846,000 | 2,195,000 | 4,036,000 | 3,107,000 | 15,000 | ||||||||||||
| other receivables | 1,906,000 | 1,727,000 | 1,299,000 | 1,145,000 | 1,312,000 | 1,476,000 | 1,093,000 | 1,008,000 | 246,000 | 418,000 | 3,582,000 | 3,995,000 | 603,000 | 306,000 | 92,000 | 139,000 | 157,000 | 247,000 | 20,000 | 1,000 |
| prepaid expenses | 29,173,000 | 5,999,000 | 14,650,000 | 7,015,000 | 5,972,000 | 6,803,000 | 7,868,000 | 6,007,000 | 5,002,000 | 4,509,000 | 4,767,000 | 3,494,000 | 2,486,000 | |||||||
| total current assets | 474,429,000 | 480,773,000 | 356,705,000 | 357,117,000 | 362,588,000 | 340,724,000 | 256,131,000 | 259,277,000 | 183,476,000 | 208,646,000 | 225,375,000 | 234,078,000 | 250,283,000 | 178,755,000 | 175,952,000 | 187,088,000 | 200,904,000 | 191,451,000 | 170,655,000 | 89,072,000 |
| restricted cash, non-current | 2,563,000 | 2,563,000 | 2,562,000 | |||||||||||||||||
| inventory, non-current | 2,532,000 | 2,532,000 | 2,533,000 | 2,533,000 | 2,533,000 | |||||||||||||||
| property and equipment | 3,182,000 | 2,787,000 | 2,314,000 | 2,393,000 | 2,241,000 | 1,338,000 | 1,468,000 | 1,614,000 | 1,541,000 | 1,193,000 | 957,000 | 951,000 | 963,000 | 915,000 | 755,000 | 548,000 | ||||
| intangible assets | 7,846,000 | 8,086,000 | 8,326,000 | 8,567,000 | 3,667,000 | 3,767,000 | 3,867,000 | 3,967,000 | ||||||||||||
| operating lease right-of-use assets | 229,000 | 393,000 | 552,000 | 1,802,000 | 1,969,000 | 2,132,000 | 1,880,000 | 2,011,000 | 2,137,000 | 540,000 | 575,000 | 696,000 | 813,000 | 926,000 | 1,074,000 | 688,000 | ||||
| long-term investments | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 631,000 | 210,000 | 322,000 | 306,000 | 371,000 | 157,000 | 169,000 | ||||||||
| other assets | 1,213,000 | 616,000 | 999,000 | 888,000 | 846,000 | 1,317,000 | 1,514,000 | 1,253,000 | 1,451,000 | 529,000 | 585,000 | 583,000 | 600,000 | 887,000 | 1,126,000 | 1,615,000 | 1,525,000 | 1,330,000 | 81,000 | 1,750,000 |
| total assets | 494,994,000 | 500,750,000 | 376,991,000 | 376,300,000 | 376,844,000 | 349,278,000 | 265,491,000 | 268,332,000 | 188,927,000 | 211,214,000 | 227,863,000 | 236,465,000 | 252,828,000 | 181,483,000 | 178,907,000 | 190,412,000 | 203,450,000 | 193,954,000 | 171,972,000 | 92,185,000 |
| liabilities and stockholders' equity | ||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||
| accounts payable and other accrued liabilities | 78,641,000 | 76,375,000 | 64,789,000 | 54,543,000 | 43,526,000 | 36,570,000 | 23,691,000 | 15,351,000 | 9,459,000 | 9,049,000 | 9,910,000 | 10,181,000 | 8,938,000 | 10,805,000 | 8,680,000 | 8,119,000 | 8,985,000 | 9,433,000 | 4,347,000 | 5,624,000 |
| accrued payroll and benefits | 11,612,000 | 9,933,000 | 15,823,000 | 11,325,000 | 8,045,000 | 5,958,000 | 13,245,000 | 7,898,000 | 5,306,000 | 4,206,000 | 5,519,000 | 4,092,000 | 2,780,000 | 1,805,000 | 2,798,000 | 2,246,000 | 1,470,000 | 685,000 | 1,040,000 | 520,000 |
| total current liabilities | 90,253,000 | 86,308,000 | 80,612,000 | 65,868,000 | 51,571,000 | 42,528,000 | 36,936,000 | 23,249,000 | 14,765,000 | 13,255,000 | 15,429,000 | 14,273,000 | 11,718,000 | 12,610,000 | 11,478,000 | 10,365,000 | 10,455,000 | 10,118,000 | 5,387,000 | 6,144,000 |
| long-term debt | 72,129,000 | 71,984,000 | 71,845,000 | 71,708,000 | ||||||||||||||||
| total liabilities | 162,382,000 | 158,292,000 | 152,457,000 | 138,816,000 | 124,598,000 | 74,067,000 | 68,503,000 | 54,668,000 | 41,198,000 | 37,810,000 | 34,963,000 | 33,838,000 | 31,323,000 | 32,286,000 | 12,177,000 | 11,270,000 | 10,979,000 | 10,722,000 | 5,992,000 | 6,855,000 |
| commitments and contingencies | ||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding | ||||||||||||||||||||
| common stock | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 2,000 |
| additional paid-in capital | 738,237,000 | 727,697,000 | 584,559,000 | 574,229,000 | 566,093,000 | 555,655,000 | 441,641,000 | 416,421,000 | 311,353,000 | 305,651,000 | 301,732,000 | 297,796,000 | 294,153,000 | 216,103,000 | 213,398,000 | 210,959,000 | 208,591,000 | 205,697,000 | 198,821,000 | 3,548,000 |
| accumulated other comprehensive income | 39,000 | 85,000 | 179,000 | |||||||||||||||||
| accumulated deficit | -405,670,000 | -385,330,000 | -360,210,000 | -337,097,000 | -313,677,000 | -280,387,000 | -244,656,000 | -202,754,000 | -163,606,000 | -132,182,000 | -108,763,000 | -95,164,000 | -72,653,000 | -66,910,000 | -46,672,000 | -31,821,000 | -16,124,000 | -22,469,000 | -32,845,000 | -21,379,000 |
| total stockholders’ equity | 332,612,000 | 342,458,000 | 224,534,000 | 237,484,000 | 252,246,000 | 275,211,000 | 196,988,000 | 213,664,000 | 147,729,000 | 173,404,000 | 192,900,000 | 202,627,000 | 221,505,000 | 149,197,000 | 166,730,000 | 179,142,000 | 192,471,000 | 183,232,000 | 165,980,000 | |
| total liabilities and stockholders’ equity | 494,994,000 | 500,750,000 | 376,991,000 | 376,300,000 | 376,844,000 | 349,278,000 | 265,491,000 | 268,332,000 | 188,927,000 | 211,214,000 | 227,863,000 | 236,465,000 | 252,828,000 | 181,483,000 | 178,907,000 | 190,412,000 | ||||
| preferred stock, 0.0001 par value; 10,000,000 authorized; no shares issued and outstanding | ||||||||||||||||||||
| other long-term liabilities | 1,240,000 | 1,449,000 | 1,606,000 | 1,748,000 | 1,711,000 | 1,826,000 | 40,000 | 100,000 | 209,000 | 343,000 | 496,000 | 699,000 | 905,000 | 524,000 | 604,000 | 605,000 | 711,000 | |||
| accumulated other comprehensive gain | 346,000 | |||||||||||||||||||
| term loan | 71,578,000 | 29,933,000 | 29,819,000 | 29,708,000 | 24,607,000 | 24,515,000 | 19,434,000 | 19,356,000 | 19,262,000 | 19,180,000 | ||||||||||
| accumulated other comprehensive loss | -176,000 | -63,000 | -2,000 | -8,000 | -23,000 | -70,000 | -74,000 | -10,000 | ||||||||||||
| prepaid expenses and other current assets | 4,300,000 | 3,131,000 | 4,045,000 | 3,148,000 | 4,012,000 | 2,806,000 | 2,722,000 | |||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 authorized; no shares issued and outstanding at march 31, 2022 and december 31, 2021 | ||||||||||||||||||||
| restricted cash | 20,000 | 20,000 | 20,000 | |||||||||||||||||
| property and equipment, net of accumulated depreciation | 519,000 | 481,000 | 589,000 | 604,000 | ||||||||||||||||
| operating lease right-of-use asset | 1,190,000 | 540,000 | 584,000 | 759,000 | ||||||||||||||||
| liabilities and stockholders’ equity | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 authorized at september 30, 2021 and december 31, 2020; no shares issued and outstanding at september 30, 2021 and december 31, 2020 | ||||||||||||||||||||
| liabilities, preferred stock and stockholders’ equity | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 authorized at june 30, 2021 and december 31, 2020; no shares issued and outstanding at june 30, 2021 and december 31, 2020 | ||||||||||||||||||||
| total liabilities, preferred stock and stockholders’ equity | 203,450,000 | 193,954,000 | 171,972,000 | |||||||||||||||||
| contract asset | 7,199,000 | |||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 authorized at march 31, 2021 and december 31, 2020; no shares issued and outstanding at march 31, 2021 and december 31, 2020 | ||||||||||||||||||||
| series a preferred stock, 0.0001 par value; no shares authorized, issued and outstanding at december 31, 2020; 1,575,030 shares authorized, issued and outstanding at december 31, 2019; liquidation preference of 3,650 at december 31, 2019 | ||||||||||||||||||||
| series b preferred stock, 0.0001 par value; no shares authorized, issued and outstanding at december 31, 2020; 6,731,649 shares authorized and 6,674,909 shares issued and outstanding at december 31, 2019; liquidation preference of 60,010 at december 31, 2019 | ||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||
| preferred stock, 0.0001 par value; 10,000,000 and no shares authorized at december 31, 2020 and december 31, 2019, respectively; no shares issued and outstanding at december 31, 2020 and december 31, 2019 | ||||||||||||||||||||
| liabilities, preferred stock and stockholders’ deficit | ||||||||||||||||||||
| series a preferred stock, 0.0001 par value; 1,575,030 shares authorized, issued and outstanding at september 30, 2020 (unaudited) and december 31, 2019; liquidation preference of 3,650 at september 30, 2020 (unaudited) and december 31, 2019 | 3,564,000 | |||||||||||||||||||
| series b preferred stock, 0.0001 par value; 6,731,649 shares authorized and 6,674,909 shares issued and outstanding at september 30, 2020 (unaudited) and december 31, 2019; liquidation preference of 60,010 at september 30, 2020 (unaudited) and december 31, 2019 | 59,838,000 | |||||||||||||||||||
| series c preferred stock, 0.0001 par value; 2,857,084 shares authorized and 2,857,079 shares issued and outstanding at september 30, 2020 (unaudited) and zero shares authorized, issued or outstanding at december 31, 2019; liquidation preference of 40,000 at september 30, 2020 (unaudited) and 0 at december 31, 2019 | 39,757,000 | |||||||||||||||||||
| stockholders’ (deficit) equity: | ||||||||||||||||||||
| total stockholders’ deficit | -17,829,000 | |||||||||||||||||||
| total liabilities, preferred stock and stockholders’ deficit | 92,185,000 |
We provide you with 20 years of balance sheets for Tarsus Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Tarsus Pharmaceuticals. Explore the full financial landscape of Tarsus Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Tarsus Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.